Glioma Treatment Market Scope and Key Players Analysis by 2030
Glioma Treatment Market Report Scope
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 4.14 Billion |
| Market Size by 2030 | US$ 8.29 Billion |
| Global CAGR (2022 - 2030) | 9.1% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2030 |
| Segments Covered |
By Disease
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
COVID-19 Impact:
During the pre-COVID scenario, continuous research and development activities were carried out for the effective treatment of glioma including surgical resection followed by radio chemotherapy and chemotherapy for patients’ higher survival rate. Major players in the market with funding from the National Institute of Health were focusing on various growth strategies; for instance, R&D in nanotechnology for the options for glioma treatment. These activities were delayed for certain period, as the focus of treatment changed after the COVID-19 outbreak.
The COVID-19 pandemic disrupted healthcare systems, leading to concerns about its subsequent impact on non-COVID disease conditions. Cancer diagnosis and treatment are time-sensitive and are likely to be significantly affected by these conditions. The activities of each cancer discipline have been adversely affected by the COVID-19 pandemic. In addition, childhood malignant brain tumors are characterized by rapid growth and require early diagnosis and appropriate treatment. Therefore, delaying or modifying treatment can compromise its effectiveness and reduce patient survival. Due to the fear and pressure of SARS CoV2 infection, changes in the decision-making process of children with brain tumors may have a negative impact on their final outcome to certain extent.
Competitive Landscape and Key Companies:
Some of the prominent players operating in the global glioma treatment market are F. Hoffmann-La Roche Ltd; Arbor Pharmaceuticals, LLC; Merck and Co., Inc.; Sun Pharmaceutical Industries Ltd; Amgen Inc.; Teva Pharmaceutical Industries Ltd.; Pfizer Inc.; Amneal Pharmaceuticals, LLC; Karyopharm Therapeutics, Inc.; and Bristol Mayers Squibb Company. These companies focus on new product launches and geographical expansions to meet the growing consumer demand worldwide and increase their product range in specialty portfolios. They have a widespread global presence, which provides them to serve a large set of customers and subsequently increases their market share. The report offers trend analysis of the glioma treatment market outlook emphasizing various parameters such as technological advancements, market dynamics, and competitive landscape analysis of leading market players across the globe.
Get Free Sample For